Magnetar Financial LLC Adc Therapeutics Sa Transaction History

Magnetar Financial LLC

$3.06 Billion
Q4 2024

A detailed history of Magnetar Financial LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Magnetar Financial LLC holds 55,762 shares of ADCT stock, worth $74,163. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,762

Previous 55,762 -0.0%

Holding current value

$74,163

Previous $175,000 37.14%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.92 - $5.45 $136,523 - $387,527	-71,106 Reduced 56.05%	55,762 $108,000
Q4 2022 Feb 14, 2023	SELL	$2.87 - $5.24 $114,800 - $209,600	-40,000 Reduced 23.97%	126,868 $487,000
Q3 2022 Nov 14, 2022	SELL	$4.66 - $10.31 $3,867 - $8,557	-830 Reduced 0.49%	166,868 $804,000
Q1 2022 May 16, 2022	BUY	$13.28 - $20.03 $531,200 - $801,200	40,000 Added 31.32%	167,698 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$19.29 - $31.51 $48,225 - $78,775	2,500 Added 2.0%	127,698 $2.58 Million
Q3 2021 Nov 12, 2021	SELL	$20.45 - $30.0 $306,750 - $450,000	-15,000 Reduced 10.7%	125,198 $3.4 Million
Q2 2021 Aug 06, 2021	BUY	$20.38 - $27.04 $611,400 - $811,200	30,000 Added 27.22%	140,198 $3.41 Million
Q4 2020 Feb 12, 2021	SELL	$25.26 - $38.02 $38.2 Million - $57.5 Million	-1,513,012 Reduced 93.21%	110,198 $3.53 Million
Q3 2020 Nov 16, 2020	BUY	$32.87 - $51.05 $1.96 Million - $3.05 Million	59,772 Added 3.82%	1,623,210 $49.4 Million
Q2 2020 Aug 14, 2020	BUY	$29.65 - $46.81 $46.4 Million - $73.2 Million	1,563,438 New	1,563,438 $64.4 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

55M

Call Options Held

24.1K

Put Options Held

44.7K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $103M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Magnetar Financial LLC with notifications on news.

Account

Magnetar Financial LLC Adc Therapeutics Sa Transaction History